Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:

Schedule

*Product:*	Ocrevus
Active Ingredient:	Ocrelizumab 300mg
Dosage Form:	Concentrate for infusion
New Zealand Sponsor:	Roche Products (NZ) Limited
Manufacturers:	Roche Diagnostics GmbH, Mannheim, Germany F Hoffmann-La Roche AG, Kaiseraugst. Switzerland

*Product:*	Trajentamet (2.5mg/500mg)
Active Ingredients:	Linagliptin 2.5mg Metformin hydrochloride 500mg
Dosage Form:	Film coated tablet
New Zealand Sponsor:	Boehringer Ingelheim (NZ) Limited
Manufacturers:	Dragenopharm, Apotheker Puschl GmbH & Co. KG, Tittmoning, Germany Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany

*Product:*	Trajentamet (2.5mg/850mg)
Active Ingredients:	Linagliptin 2.5mg Metformin hydrochloride 850mg
Dosage Form:	Film coated tablet
New Zealand Sponsor:	Boehringer Ingelheim (NZ) Limited
Manufacturers:	Dragenopharm, Apotheker Puschl GmbH & Co. KG, Tittmoning, Germany Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany

*Product:*	Trajentamet (2.5mg/1000mg)
Active Ingredients:	Linagliptin 2.5mg Metformin hydrochloride 1000mg
Dosage Form:	Film coated tablet
New Zealand Sponsor:	Boehringer Ingelheim (NZ) Limited
Manufacturers:	Dragenopharm, Apotheker Puschl GmbH & Co. KG, Tittmoning, Germany Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany

Dated this 6th day of December 2024.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

Tags

Notice Number

Schedule